Efficacy and Safety Study of Satralizumab (SA237) as Monotherapy to Treat Participants With Neuromyelitis Optica (NMO) and Neuromyelitis Optica Spectrum Disorder (NMOSD)
Autoimmune Disorder Neuromyelitis Optica Neuromyelitis optica spectrum disorder (NMOSD)
For the latest version of this information please go to www.forpatients.roche.com